There is an increasing frequency of food allergy and intolerance in infants in the developed world. A substantial body of evidence suggests that this increase is due to the failure of the 'priming' activities of the normal flora of human intestinal tracts on the immature immune system in advanced societies. This may be caused by over hygienic conditions in hospitals, use of antibiotics and other modern techniques in infancy. This project aims to produce a nutritional supplement containing probation bacteria isolated from the bacterial flora of the infant gastrointestinal tract. These will prime the gastrointestinal tract to promote the optimal maturation of the infant gut mussel immune system and minimise subsequent allergic sensitivities. The project will thus enhance the health of infants suffering from food allergy and intolerance - an important section of the population. Research objectives are to identify key microorganisms; develop a product comprising these microorganisms; carryout safety testing and design and implement at least three clinical trials of the product before launching it in the marketplace.
Funding SchemeEAW - Exploratory awards